VEGF gene therapy: Therapeutic angiogenesis in the clinic and beyond

Gene Therapy

Volumn 19, Issue 6, 2012, Pages 622-629

  Giacca, M ^a   Zacchigna, S ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

angiogenesis; clinical trial; myocardial infarction; VEGF

Indexed keywords

PLACEBO; PLASMID DNA; VASCULOTROPIN; VASCULOTROPIN 165;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CORONARY ARTERY DISEASE; GENE THERAPY; HUMAN; LEG EDEMA; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; REVIEW;

CLINICAL TRIALS AS TOPIC; CORONARY ARTERY DISEASE; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862026102     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.17     Document Type: Review

References (95)

1. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002; 2: 795-803. (Pubitemid 37328914)
2. Ide AG, Baker NH, Warren SL. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol 1939; 42: 891-899.
3. Folkman J, Merler E, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971; 133: 275-288.
4. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
5. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161: 851-858. (Pubitemid 19162712)
6. Autiero M, Waltenberger J, Communi D, Kranz A, Moons L, Lambrechts D et al. Role of PlGF in the intra-and intermolecular cross talk between the VEGF receptors Flt1 and Flk1. Nat Med 2003; 9: 936-943. (Pubitemid 36889938)
7. Terman BI, Dougher-Vermazen M, Carrion ME, Dimitrov D, Armellino DC, Gospodarowicz D et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187: 1579-1586.
8. Fujisawa H, Kitsukawa T. Receptors for collapsin/semaphorins. Curr Opin Neurobiol 1998; 8: 587-592. (Pubitemid 28488419)
9. Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 1998; 92: 735-745. (Pubitemid 28155313)
10. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
11. Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873-887.
12. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-478. (Pubitemid 46823443)
13. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling-in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
14. Giacca M. Non-redundant functions of the protein isoforms arising from alternative splicing of the VEGF-A pre-mRNA. Transcription 2010; 1: 149-153.
15. Rissanen TT, Yla-Herttuala S. Current status of cardiovascular gene therapy. Mol Ther 2007; 15: 1233-1247. (Pubitemid 46965318)
16. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ et al. The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation 2003; 107: 1359-1365. (Pubitemid 36350732)
17. Sato K, Laham RJ, Pearlman JD, Novicki D, Sellke FW, Simons M et al. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg 2000; 70: 2113-2118. (Pubitemid 32015318)
18. Isner JM. Vascular endothelial growth factor: gene therapy and therapeutic angiogenesis. Am J Cardiol 1998; 82: 63S-64S.
19. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara Tet al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996; 348: 370-374. (Pubitemid 26261511)
20. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, Walsh K et al. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 1998; 97: 1114-1123. (Pubitemid 28152883)
21. Kim HJ, Jang SY, Park JI, Byun J, Kim DI, Do YS et al. Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 2004; 36: 336-344. (Pubitemid 39279529)
22. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, Kearney M et al. Lowerextremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 2000; 132: 880-884. (Pubitemid 30346850)
23. Losordo DW, Vale PR, Symes JF, Dunnington CH, Esakof DD, Maysky M et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 1998; 98: 2800-2804. (Pubitemid 29003959)
24. Symes JF, Losordo DW, Vale PR, Lathi KG, Esakof DD, Mayskiy M et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg 1999; 68: 830-836; discussion 836-837.
25. Fortuin FD, Vale P, Losordo DW, Symes J, DeLaria GA, Tyner JJ et al. One-year follow-up of direct myocardial gene transfer of vascular endothelial growth factor-2 using naked plasmid deoxyribonucleic acid by way of thoracotomy in no-option patients. Am J Cardiol 2003; 92: 436-439. (Pubitemid 36959880)
26. Reilly JP, Grise MA, Fortuin FD, Vale PR, Schaer GL, Lopez J et al. Long-term (2-year) clinical events following transthoracic intramyocardial gene transfer of VEGF-2 in nooption patients. J Interv Cardiol 2005; 18: 27-31. (Pubitemid 40468771)
27. Vale PR, Losordo DW, Milliken CE, Maysky M, Esakof DD, Symes JF et al. Left ventricular electromechanical mapping to assess efficacy of phVEGF (165) gene transfer for therapeutic angiogenesis in chronic myocardial ischemia. Circulation 2000; 102: 965-974.
28. Sarkar N, Ruck A, Kallner G, Y-Hassan S, Blomberg P, Islam KB et al. Effects of intramyocardial injection of phVEGF-A165 as sole therapy in patients with refractory coronary artery disease-12-month follow-up: angiogenic gene therapy. J Intern Med 2001; 250: 373-381. (Pubitemid 32990045)
29. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N et al. Phase 1/placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002; 105: 2012-2018. (Pubitemid 34465261)
30. Mendiz O, Favaloro L, Diez M, Valdivieso L, Bercovich A, Criscuolo M et al. Abstract 15235: high-dose plasmid VEGF gene transfer in patients with severe coronary artery disease: final results of the first Latin American trial of gene therapy in myocardial ischemia. Circulation 2011; 124 (Suppl.): A15235.
31. Gyongyosi M, Khorsand A, Zamini S, Sperker W, Strehblow C, Kastrup J et al. NOGAguided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation 2005; 112 (Suppl): I157-I165. (Pubitemid 41266668)
32. Kastrup J, Jorgensen E, Ruck A, Tagil K, Glogar D, Ruzyllo W et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris. A randomized double-blind placebo-controlled study: the Euroinject One Trial. J Am Coll Cardiol 2005; 45: 982-988. (Pubitemid 40432426)
33. Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009; 17: 1109-1115.
34. Ripa RS, Wang Y, Jorgensen E, Johnsen HE, Hesse B, Kastrup J. Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocytecolony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease. Eur Heart J 2006; 27: 1785-1792. (Pubitemid 44297382)
35. Kukula K, Chojnowska L, Dabrowski M, Witkowski A, Chmielak Z, Skwarek M et al. Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J 2011; 161: 581-589.
36. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, Hooymans JM et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a doubleblind randomized trial. Hum Gene Ther 2006; 17: 683-691. (Pubitemid 43970708)
37. Liu PQ, Rebar EJ, Zhang L, Liu Q, Jamieson AC, Liang Y et al. Regulation of an endogenous locus using a panel of designed zinc finger proteins targeted to accessible chromatin regions. Activation of vascular endothelial growth factor A. J Biol Chem 2001; 276: 11323-11334. (Pubitemid 38089322)
38. Rebar EJ, Huang Y, Hickey R, Nath AK, Meoli D, Nath S et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 2002; 8: 1427-1432. (Pubitemid 36019428)
39. Dai Q, Huang J, Klitzman B, Dong C, Goldschmidt-Clermont PJ, March KL et al. Engineered zinc finger-activating vascular endothelial growth factor transcription factor plasmid DNA induces therapeutic angiogenesis in rabbits with hindlimb ischemia. Circulation 2004; 110: 2467-2475. (Pubitemid 39407355)
40. Yu J, Lei L, Liang Y, Hinh L, Hickey RP, Huang Y et al. An engineered VEGF-activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced-age mice. FASEB J 2006; 20: 479-481. (Pubitemid 46671222)
41. Tafuro S, Ayuso E, Zacchigna S, Zentilin L, Moimas S, Dore F et al. Inducible adenoassociated virus vectors promote functional angiogenesis in adult organisms via regulated vascular endothelial growth factor expression. Cardiovasc Res 2009; 83: 663-671.
42. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, Norgren L et al. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 2011; 377: 1929-1937.
43. Rajagopalan S, Shah M, Luciano A, Crystal R, Nabel EG. Adenovirus-mediated gene transfer of VEGF (121) improves lower-extremity endothelial function and flow reserve. Circulation 2001; 104: 753-755. (Pubitemid 32762670)
44. Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, Pak R et al. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 2002; 90: 512-516. (Pubitemid 35251823)
45. Rajagopalan S, Mohler III E, Lederman RJ, Saucedo J, Mendelsohn FO, Olin J et al. Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial. Am Heart J 2003; 145: 1114-1118. (Pubitemid 36688266)
46. Rajagopalan S, Mohler III ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 2003; 108: 1933-1938. (Pubitemid 37296537)
47. Rosengart TK, Lee LY, Patel SR, Sanborn TA, Parikh M, Bergman GW et al. Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 1999; 100: 468-474. (Pubitemid 29360154)
48. Stewart DJ, Hilton JD, Arnold JM, Gregoire J, Rivard A, Archer SL et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF (121) (AdVEGF121) versus maximum medical treatment. Gene Therapy 2006; 13: 1503-1511. (Pubitemid 44574158)
49. Fuchs S, Dib N, Cohen BM, Okubagzi P, Diethrich EB, Campbell A et al. A randomized, double-blind, placebo-controlled, multicenter, pilot study of the safety and feasibility of catheter-based intramyocardial injection of AdVEGF121 in patients with refractory advanced coronary artery disease. Catheter Cardiovasc Interv 2006; 68: 372-378. (Pubitemid 44330674)
50. Kastrup J, Jorgensen E, Fuchs S, Nikol S, Botker HE, Gyongyosi M et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention 2011; 6: 813-818.
51. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, Alhava E et al. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 2002; 6: 127-133. (Pubitemid 36124280)
52. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003; 107: 2677-2683. (Pubitemid 36667240)
53. Hedman M, Muona K, Hedman A, Kivela A, Syvanne M, Eranen J et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Therapy 2009; 16: 629-634.
54. Muona K, Makinen K, Hedman M, Manninen H, Yla-Herttuala S. 10-year safety followup in patients with local VEGF gene transfer to ischemic lower limb. Gene Therapy 2011; e-pub ahead of print 21 July 2011; doi:10.1038/gt.2011.109.
55. Rutanen J, Rissanen TT, Markkanen JE, Gruchala M, Silvennoinen P, Kivela A et al. Adenoviral catheter-mediated intramyocardial gene transfer using the mature form of vascular endothelial growth factor-D induces transmural angiogenesis in porcine heart. Circulation 2004; 109: 1029-1035. (Pubitemid 38282857)
56. Fuster V, Charlton P, Boyd A. Clinical protocol. A phase IIb, randomized, multicenter, double-blind study of the efficacy and safety of Trinam (EG004) in stenosis prevention at the graft-vein anastomosis site in dialysis patients. Hum Gene Ther 2001; 12: 2025-2027.
57. Gilgenkrantz H, Duboc D, Juillard V, Couton D, Pavirani A, Guillet JG et al. Transient expression of genes transferred in vivo into heart using first-generation adenoviral vectors: role of the immune response. Hum Gene Ther 1995; 6: 1265-1274.
58. Daya S, Berns KI. Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 2008; 21: 583-593.
59. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011; 12: 341-355.
60. Arsic N, Zentilin L, Zacchigna S, Santoro D, Stanta G, Salvi S et al. Induction of functional neovascularization by combined VEGF and angiopoietin-1 gene transfer using AAV vectors. Mol Ther 2003; 7: 450-459. (Pubitemid 36553413)
61. Cervelli T, Palacios JA, Zentilin L, Mano M, Schwartz RA, Weitzman MD et al. Processing of recombinant AAV genomes occurs in specific nuclear structures that overlap with foci of DNA-damage-response proteins. J Cell Sci 2008; 121 (Part 3): 349-357. (Pubitemid 351356706)
62. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G et al. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 2002; 417: 954-958. (Pubitemid 34716872)
63. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002; 8: 831-840.
64. Perelman N, Selvaraj SK, Batra S, Luck LR, Erdreich-Epstein A, Coates TD et al. Placenta growth factor activates monocytes and correlates with sickle cell disease severity. Blood 2003; 102: 1506-1514. (Pubitemid 36988063)
65. Oe H, Kaido T, Mori A, Onodera H, Imamura M. Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepatogastroenterology 2005; 52: 1393-1397. (Pubitemid 41391000)
66. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 1999; 5: 623-628. (Pubitemid 29289424)
67. Maes C, Carmeliet P, Moermans K, Stockmans I, Smets N, Collen D et al. Impaired angiogenesis and endochondral bone formation in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Mech Dev 2002; 111: 61-73. (Pubitemid 34136979)
68. Eremina V, Sood M, Haigh J, Nagy A, Lajoie G, Ferrara N et al. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 2003; 111: 707-716. (Pubitemid 36278589)
69. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658. (Pubitemid 36278583)
70. Zacchigna S, Lambrechts D, Carmeliet P. Neurovascular signalling defects in neurodegeneration. Nat Rev Neurosci 2008; 9: 169-181. (Pubitemid 351272665)
71. Sondell M, Sundler F, Kanje M. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal outgrowth through the flk-1 receptor. Eur J Neurosci 2000; 12: 4243-4254. (Pubitemid 32037835)
72. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA 2000; 97: 10242-10247.
73. Silverman WF, Krum JM, Mani N, Rosenstein JM. Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures. Neuroscience 1999; 90: 1529-1541. (Pubitemid 29170166)
74. Storkebaum E, Lambrechts D, Dewerchin M, Moreno-Murciano MP, Appelmans S, Oh H et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 2005; 8: 85-92. (Pubitemid 41236736)
75. Schratzberger P, Walter DH, Rittig K, Bahlmann FH, Pola R, Curry C et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001; 107: 1083-1092. (Pubitemid 32422905)
76. Isner JM, Ropper A, Hirst K. VEGF gene transfer for diabetic neuropathy. Hum Gene Ther 2001; 12: 1593-1594.
77. Ropper AH, Gorson KC, Gooch CL, Weinberg DH, Pieczek A, Ware JH et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009; 65: 386-393.
78. Lambrechts D, Carmeliet P. VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. Biochim Biophys Acta 2006; 1762: 1109-1121. (Pubitemid 44781175)
79. Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, Shibuya M et al. Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 2001; 188: 359-368. (Pubitemid 32777178)
80. Storkebaum E, Ruiz de Almodovar C, Meens M, Zacchigna S, Mazzone M, Vanhoutte G et al. Impaired autonomic regulation of resistance arteries in mice with low vascular endothelial growth factor or upon vascular endothelial growth factor trap delivery. Circulation 2010; 122: 273-281.
81. Arsic N, Zacchigna S, Zentilin L, Ramirez-Correa G, Pattarini L, Salvi A et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther 2004; 10: 844-854. (Pubitemid 39419911)
82. Messina S, Mazzeo A, Bitto A, Aguennouz M, Migliorato A, De Pasquale MG et al. VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. FASEB J 2007; 21: 3737-3746. (Pubitemid 350075161)
83. Azambuja AP, Portillo-Sanchez V, Rodrigues MV, Omae SV, Schechtman D, Strauss BE et al. Retinoic acid and VEGF delay smooth muscle relative to endothelial differentiation to coordinate inner and outer coronary vessel wall morphogenesis. Circ Res 2010; 107: 204-216.
84. Ferrarini M, Arsic N, Recchia FA, Zentilin L, Zacchigna S, Xu X et al. Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ Res 2006; 98: 954-961.
85. Pepe M, Mamdani M, Zentilin L, Csiszar A, Qanud K, Zacchigna S et al. Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ Res 2010; 106: 1893-1903.
86. Zentilin L, Puligadda U, Lionetti V, Zacchigna S, Collesi C, Pattarini L et al. Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J 2009; 24: 1467-1478.
87. Zacchigna S, Pattarini L, Zentilin L, Moimas S, Carrer A, Sinigaglia M et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis. J Clin Invest 2008; 118: 2062-2075. (Pubitemid 351872326)
88. Bry M, Kivela R, Holopainen T, Anisimov A, Tammela T, Soronen J et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 2010; 122: 1725-1733.
89. Levy AP, Levy NS, Loscalzo J, Calderone A, Takahashi N, Yeo KT et al. Regulation of vascular endothelial growth factor in cardiac myocytes. Circ Res 1995; 76: 758-766.
90. Xu XH, Xu J, Xue L, Cao HL, Liu X, Chen YJ. VEGF attenuates development from cardiac hypertrophy to heart failure after aortic stenosis through mitochondrial mediated apoptosis and cardiomyocyte proliferation. J Cardiothorac Surg 2011; 6: 54.
91. Rottbauer W, Just S, Wessels G, Trano N, Most P, Katus HA et al. VEGF-PLCgamma1 pathway controls cardiac contractility in the embryonic heart. Genes Dev 2005; 19: 1624-1634. (Pubitemid 41003004)
92. Chintalgattu V, Nair DM, Katwa LC. Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J Mol Cell Cardiol 2003; 35: 277-286. (Pubitemid 36379171)
93. Tang JM, Wang JN, Zhang L, Zheng F, Yang JY, Kong X et al. VEGF/SDF-1 promotes cardiac stem cell mobilization and myocardial repair in the infarcted heart. Cardiovasc Res 2011; 91: 402-411.
94. Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 2009; 6: 465-477.
95. Stewart DJ, Kutryk MJ, Fitchett D, Freeman M, Camack N, Su Y et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther 2009; 17: 1109-1115.